mRNA Therapy Delivers Collagen III Directly to Aging Skin Cells
Scientists used lipid nanoparticle-delivered hCOL3A1 mRNA to reverse UVB-induced skin aging in cells and mice, restoring collagen without toxicity.
Summary
Researchers engineered human collagen III (hCOL3A1) mRNA encapsulated in lipid nanoparticles (LNPs) and tested it against UVB-induced photoaging in human fibroblasts and a mouse model. The mRNA instructed skin cells to produce their own full-length, biologically active collagen III — bypassing the limitations of injected recombinant proteins. In cell experiments, the therapy reduced oxidative stress, senescence, and apoptosis while boosting proliferation and migration. In mice, it restored dermal thickness, collagen content, and skin barrier function without triggering immune reactions or systemic toxicity. Transcriptome analysis confirmed the treatment reversed UVB-driven gene expression changes and reinstated normal fibroblast signaling pathways, positioning mRNA therapy as a promising next-generation tool for skin rejuvenation.
Detailed Summary
Skin photoaging — driven primarily by cumulative UV radiation — degrades dermal collagen, generates reactive oxygen species, and induces cellular senescence, producing visible wrinkles, loss of elasticity, and structural deterioration. Type III collagen is particularly important for skin elasticity and proper fibril organization, yet existing collagen-based therapies face steep hurdles: animal-derived collagen risks immunogenicity, recombinant proteins lack full-length structure and proper post-translational modifications, and retinoic acid (a standard treatment) causes irritation and poor patient compliance. This study asked whether delivering mRNA encoding human collagen III directly to skin cells could overcome these barriers.
The team synthesized hCOL3A1 mRNA with two key stability modifications: UTP was replaced by 1-methylpseudouridine (m1Ψ) to reduce innate immune activation and improve transcript longevity, and a 5' m7G cap was added to enhance translation efficiency. The mRNA was encapsulated in LNPs formulated with the ionizable lipid SM-102, DSPC, cholesterol, and DMG-PEG2000 — closely mirroring the Moderna COVID-19 vaccine formulation. In vitro, human foreskin fibroblasts (HFF-1) were subjected to a validated UVB photoaging protocol (50 mJ/cm², repeated dosing), and treated with hCOL3A1 mRNA either before or after irradiation. In vivo, a murine UVB photoaging model received topical or intradermal LNP-mRNA treatments, with retinoic acid serving as the positive control.
In cell studies, hCOL3A1 mRNA significantly reduced ROS levels, decreased SA-β-Gal-positive senescent cells, lowered p21 expression (a key senescence marker), and reduced apoptosis. Proliferation and wound-closure migration were both meaningfully improved compared to UVB-irradiated controls. Critically, pre-treatment outperformed post-treatment, suggesting a protective window of opportunity. Western blot confirmed successful FLAG-tagged collagen III protein production in transfected cells, and RT-qPCR verified that expressed collagen III was exogenous mRNA-derived rather than endogenous upregulation.
In the mouse photoaging model, hCOL3A1 mRNA treatment improved transepidermal water loss (TEWL) and skin hydration — two primary measures of barrier integrity — and significantly increased dermal thickness and collagen density as assessed by Masson's trichrome and Sirius red staining. Senescence markers (p21, p16) were reduced in treated skin. Crucially, liver enzyme panels, body weight, and histological organ assessments showed no systemic toxicity, and cytokine profiling indicated no measurable immunogenic response — a meaningful safety signal for a nucleic acid therapeutic.
Transcriptome (RNA-seq) analysis provided mechanistic depth: UVB irradiation had dysregulated pathways involved in ECM organization, collagen metabolism, and fibroblast activation, and hCOL3A1 mRNA treatment substantially reversed these changes, restoring expression profiles closer to healthy baseline. Pathways related to TGF-β signaling, focal adhesion, and PI3K-Akt were among those normalized. The authors acknowledge that long-term durability data, optimal dosing regimens, and human clinical validation remain outstanding, and that the mRNA's transient expression window means periodic retreatment would likely be needed.
Key Findings
- hCOL3A1 mRNA-LNPs reduced UVB-induced ROS, senescence (SA-β-Gal, p21), and apoptosis in human fibroblasts.
- Pre-treatment with hCOL3A1 mRNA conferred greater cell viability protection than post-UVB treatment (p<0.001).
- Murine photoaging model showed restored dermal collagen density, increased dermal thickness, and improved skin barrier function.
- No systemic toxicity, organ damage, or immunogenic cytokine response was detected in treated mice.
- RNA-seq revealed hCOL3A1 mRNA reversed UVB-driven transcriptome changes, restoring ECM and fibroblast signaling pathways.
Methodology
The study used UVB-irradiated HFF-1 human fibroblasts (50 mJ/cm², repeated dosing) and a murine photoaging model as dual experimental platforms. hCOL3A1 mRNA was modified with m1Ψ and m7G cap for stability, encapsulated in SM-102-based LNPs, and validated by HPLC, mass spectrometry, RiboGreen assay, and DLS. Outcomes included ROS fluorescence, SA-β-Gal staining, western blot, RT-qPCR, histology, TEWL, and full transcriptome (RNA-seq) analysis.
Study Limitations
The study is preclinical only — mouse skin physiology differs substantially from human skin, and no human trials have been conducted. mRNA expression is transient, meaning repeated treatments would be required, and optimal dosing frequency has not been established. Long-term efficacy, biodistribution data, and comparison against established clinical standards beyond retinoic acid are still needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: